TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Subacute Stroke Recovery (Upper Extremity Motor Function): Bimanual Coordination Training
Brief Summary: The purpose of this study was to determine the effect of two amounts of treatment therapy on post stroke motor recovery in the arms. The therapy is bilateral movement training combined with electrical stimulation on the impaired limb.


Options:
A: Arm Label: Intensive Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Walking | Arm Label: Conventional Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional Physical Therapy | Intervention Type: BEHAVIORAL; Name: Intensive Walking; Assigned to Arm(s): Intensive Walking | Intervention Type: BEHAVIORAL; Name: Conventional Physical Therapy; Assigned to Arm(s): Conventional Physical Therapy
B: Arm Label: High Intensity; Type: EXPERIMENTAL; Interventions: Behavioral: Bilateral movements and neuromuscular electrical stimulation | Arm Label: Low Intensity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Bilateral movements and neuromuscular electrical stimulation | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Bilateral movements and sham electrical stimulation | Intervention Type: BEHAVIORAL; Name: Bilateral movements and neuromuscular electrical stimulation; Assigned to Arm(s): High Intensity | Intervention Type: BEHAVIORAL; Name: Bilateral movements and neuromuscular electrical stimulation; Assigned to Arm(s): Low Intensity | Intervention Type: BEHAVIORAL; Name: Bilateral movements and sham electrical stimulation; Assigned to Arm(s): Control
C: Arm Label: Exercise + practice; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise, Behavioral: Practice | Arm Label: Rest + practice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Practice | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise + practice | Intervention Type: BEHAVIORAL; Name: Practice; Assigned to Arm(s): Exercise + practice, Rest + practice
D: Arm Label: ASAP; Type: EXPERIMENTAL; Interventions: Behavioral: Accelerated Skill Acquisition Program (ASAP) | Arm Label: DEUCC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dose-Equivalent Usual & Customary Care - DEUCC | Arm Label: UCC; Type: OTHER; Interventions: Behavioral: Usual and Customary Care - UCC | Intervention Type: BEHAVIORAL; Name: Accelerated Skill Acquisition Program (ASAP); Assigned to Arm(s): ASAP | Intervention Type: BEHAVIORAL; Name: Dose-Equivalent Usual & Customary Care - DEUCC; Assigned to Arm(s): DEUCC | Intervention Type: BEHAVIORAL; Name: Usual and Customary Care - UCC; Assigned to Arm(s): UCC

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Subacute Stroke Recovery (Upper Extremity Motor Function): Bimanual Coordination Training
Brief Summary: The purpose of this study was to determine the effect of two amounts of treatment therapy on post stroke motor recovery in the arms. The therapy is bilateral movement training combined with electrical stimulation on the impaired limb.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: physical rehabilitation | Intervention Type: BEHAVIORAL; Name: physical rehabilitation; Assigned to Arm(s): Intervention
B: Arm Label: Exercise + practice; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise, Behavioral: Practice | Arm Label: Rest + practice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Practice | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise + practice | Intervention Type: BEHAVIORAL; Name: Practice; Assigned to Arm(s): Exercise + practice, Rest + practice
C: Arm Label: RBX + tDCS; Type: EXPERIMENTAL; Interventions: Drug: reboxetine, Device: tDCS verum | Arm Label: RBX + sham stimulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: reboxetine, Device: tDCS sham | Arm Label: PLC + tDCS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Device: tDCS verum | Arm Label: PLC + sham stimulation; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo, Device: tDCS sham | Intervention Type: DRUG; Name: reboxetine; Assigned to Arm(s): RBX + sham stimulation, RBX + tDCS | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLC + sham stimulation, PLC + tDCS | Intervention Type: DEVICE; Name: tDCS verum; Assigned to Arm(s): PLC + tDCS, RBX + tDCS | Intervention Type: DEVICE; Name: tDCS sham; Assigned to Arm(s): PLC + sham stimulation, RBX + sham stimulation
D: Arm Label: High Intensity; Type: EXPERIMENTAL; Interventions: Behavioral: Bilateral movements and neuromuscular electrical stimulation | Arm Label: Low Intensity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Bilateral movements and neuromuscular electrical stimulation | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Bilateral movements and sham electrical stimulation | Intervention Type: BEHAVIORAL; Name: Bilateral movements and neuromuscular electrical stimulation; Assigned to Arm(s): High Intensity | Intervention Type: BEHAVIORAL; Name: Bilateral movements and neuromuscular electrical stimulation; Assigned to Arm(s): Low Intensity | Intervention Type: BEHAVIORAL; Name: Bilateral movements and sham electrical stimulation; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
Brief Summary: The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients. All consecutive consenting patients diagnosed with WHO Group I PAH according to specific hemodynamic criteria at participating institutions will be enrolled. Participating patients will be followed for a minimum of five years from the time of enrollment.


Options:
A: N/A
B: Arm Label: exercise training group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise training | Arm Label: Control group without exercise training; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): exercise training group
C: Arm Label: Patients with PAH; Type: EXPERIMENTAL; Interventions: Other: home cardiac rehabilitation and respiratory rehabilitation | Arm Label: Patients with HFREF; Type: EXPERIMENTAL; Interventions: Other: home cardiac rehabilitation and respiratory rehabilitation | Arm Label: Patients with IHD; Type: EXPERIMENTAL; Interventions: Other: home cardiac rehabilitation and respiratory rehabilitation | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: home cardiac rehabilitation and respiratory rehabilitation; Assigned to Arm(s): Patients with HFREF, Patients with IHD, Patients with PAH
D: Arm Label: Exercise and Respiratory Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise and Respiratory Training | Intervention Type: BEHAVIORAL; Name: Exercise and Respiratory Training; Assigned to Arm(s): Exercise and Respiratory Training

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
Brief Summary: The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients. All consecutive consenting patients diagnosed with WHO Group I PAH according to specific hemodynamic criteria at participating institutions will be enrolled. Participating patients will be followed for a minimum of five years from the time of enrollment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Aerobic exercise | Intervention Type: OTHER; Name: Aerobic exercise; Assigned to Arm(s): 1, 2
B: Arm Label: exercise training group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise training | Arm Label: Control group without exercise training; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): exercise training group
C: N/A
D: Arm Label: Exercise and Respiratory Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise and Respiratory Training | Intervention Type: BEHAVIORAL; Name: Exercise and Respiratory Training; Assigned to Arm(s): Exercise and Respiratory Training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Assess Safety, Reactogenicity & Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine, Co-admin With GSK Biologicals' MMRV Vaccine in Children (2nd yr of Life) Primed With the Pneumococcal Conjugate Vaccine in Study 105553.
Brief Summary: This study will evaluate the safety, reactogenicity and immunogenicity of a booster dose of the pneumococcal conjugate vaccine, co-admin with a 1st dose or a 2nd dose of MMRV vaccine at 12-14 or respectively 14-16 months of age in children primed with the pneumococcal conjugate vaccine in study 105553. Antibody persistence will be evaluated at 8-10 months after completion of the 3-dose immunization course in study 105553. The immunogenicity, safety and reactogenicity of the 1st and 2nd dose of MMRV vaccine will also be evaluated when co-admin with the pneumococcal conjugate vaccine between 12-16 months of age.

The study has 3 groups.

* The 1st group will receive the booster dose of pneumococcal conjugate vaccine + 1st dose of MMRV vaccine at 12-14 mo of age and the booster dose of Infanrix hexa™+ 2nd dose of MMRV vaccine at 14-16 mo of age.
* The 2nd group will receive the booster dose of Infanrix hexa™ + 1st dose of MMRV vaccine at 12-14 mo of age and the booster dose of pneumococcal conjugate vaccine + 2nd dose of MMRV vaccine at 14-16 mo of age.
* The 3rd group will receive the booster dose of pneumococcal conjugate vaccine + the booster dose of Infanrix hexa™ at 12-14 mo. Subjects will be offered one dose of Priorix™ and Varilrix™ at 14-16 mo of age, outside the study.


Options:
A: Arm Label: MMRV Group; Type: EXPERIMENTAL; Interventions: Biological: Priorix-tetra™ | Arm Label: OKAH Group; Type: EXPERIMENTAL; Interventions: Biological: Priorix™, Biological: Varilrix™ | Arm Label: MMR Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Priorix™ | Intervention Type: BIOLOGICAL; Name: Priorix-tetra™; Assigned to Arm(s): MMRV Group | Intervention Type: BIOLOGICAL; Name: Priorix™; Assigned to Arm(s): MMR Group, OKAH Group | Intervention Type: BIOLOGICAL; Name: Varilrix™; Assigned to Arm(s): OKAH Group
B: Arm Label: HAV Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix® | Arm Label: HAV+MMR+V Group; Type: EXPERIMENTAL; Interventions: Biological: Havrix®, Biological: M-M-R®II, Biological: VARIVAX® | Arm Label: MMR+V→HAV Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix®, Biological: M-M-R®II, Biological: VARIVAX® | Intervention Type: BIOLOGICAL; Name: Havrix®; Assigned to Arm(s): HAV Group, HAV+MMR+V Group, MMR+V→HAV Group | Intervention Type: BIOLOGICAL; Name: M-M-R®II; Assigned to Arm(s): HAV+MMR+V Group, MMR+V→HAV Group | Intervention Type: BIOLOGICAL; Name: VARIVAX®; Assigned to Arm(s): HAV+MMR+V Group, MMR+V→HAV Group
C: Intervention Type: BIOLOGICAL; Name: 10 valent pneumococcal conjugate (vaccine); Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Noradrenalin vs Terlipressin in Patients With Hepatorenal Syndrome.A Prospective, Randomized Study
Brief Summary: The purpose of this study is to determine whether noradrenalin is as effective and safe as terlipressin in the treatment of hepatorenal syndrome


Options:
A: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): N/A
C: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Terlipressin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Noradrenalin | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Noradrenalin; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Noradrenalin vs Terlipressin in Patients With Hepatorenal Syndrome.A Prospective, Randomized Study
Brief Summary: The purpose of this study is to determine whether noradrenalin is as effective and safe as terlipressin in the treatment of hepatorenal syndrome


Options:
A: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Terlipressin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Noradrenalin | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Noradrenalin; Assigned to Arm(s): 1
C: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Terlipressin and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Arm Label: Noradrenaline and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Intervention Type: DRUG; Name: Noradrenaline; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Noradrenalin vs Terlipressin in Patients With Hepatorenal Syndrome.A Prospective, Randomized Study
Brief Summary: The purpose of this study is to determine whether noradrenalin is as effective and safe as terlipressin in the treatment of hepatorenal syndrome


Options:
A: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Terlipressin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Noradrenalin | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Noradrenalin; Assigned to Arm(s): 1
D: Arm Label: Terlipressin and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Arm Label: Noradrenaline and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Intervention Type: DRUG; Name: Noradrenaline; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare the efficacy and safety of intravitreal injection of bevacizumab alone versus bevacizumab combined with triamcinolone for treatment of refractory diabetic macular edema.


Options:
A: Arm Label: Cohort with routine OCT monitoring; Type: N/A; Interventions: N/A | Arm Label: Cohort without routine OCT monitoring; Type: N/A; Interventions: N/A
B: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg
C: Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.3 mg intravitreal ranibizumab | Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: 2.0 mg intravitreal aflibercept | Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: 1.25 mg intravitreal bevacizumab | Intervention Type: DRUG; Name: 2.0 mg intravitreal aflibercept; Assigned to Arm(s): Aflibercept | Intervention Type: DRUG; Name: 1.25 mg intravitreal bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: 0.3 mg intravitreal ranibizumab; Assigned to Arm(s): Ranibizumab
D: Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare the efficacy and safety of intravitreal injection of bevacizumab alone versus bevacizumab combined with triamcinolone for treatment of refractory diabetic macular edema.


Options:
A: Arm Label: AVASTIN; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: OZURDEX; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): AVASTIN | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): OZURDEX
B: Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A
C: Arm Label: Sham + intravitreal ranibizumab 0.3 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal ranibizumab 0.3 mg, Procedure: Sham injection | Arm Label: Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg; Type: EXPERIMENTAL; Interventions: Drug: intravitreal ranibizumab 0.3 mg, Drug: dexamethasone intravitreal implant | Intervention Type: DRUG; Name: intravitreal ranibizumab 0.3 mg; Assigned to Arm(s): Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg, Sham + intravitreal ranibizumab 0.3 mg | Intervention Type: DRUG; Name: dexamethasone intravitreal implant; Assigned to Arm(s): Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg | Intervention Type: PROCEDURE; Name: Sham injection; Assigned to Arm(s): Sham + intravitreal ranibizumab 0.3 mg
D: Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: triamcinolone acetonide; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare the efficacy and safety of intravitreal injection of bevacizumab alone versus bevacizumab combined with triamcinolone for treatment of refractory diabetic macular edema.


Options:
A: Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
C: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg
D: Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser photocoagulation | Arm Label: Laser with Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser photocoagulation | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser with Ranibizumab, Ranibizumab | Intervention Type: PROCEDURE; Name: Laser photocoagulation; Assigned to Arm(s): Laser, Laser with Ranibizumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised, Double Blind, Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS® Inhaler 50/100 mcg Twice Daily vs FLIXOTIDE® Inhaler 200 mcg Twice Daily
Brief Summary: Comparison of two asthma treatments by lung function measures.


Options:
A: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: budesonide/formoterol, 2x 200/6 microgram. 4 times daily; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: prednisolone, 30 mg once daily and placebo; Assigned to Arm(s): N/A
C: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol/fluticasone propionate and fluticasone propionate | Intervention Type: DRUG; Name: Salmeterol/fluticasone propionate and fluticasone propionate; Assigned to Arm(s): Arm 1

Answer: D